Global CEO Excellence 2017

20 CEO MONTHLY / GLOBAL CEO EXCELLENCE AWARDS 2017 , Bettorlogic develop betting tools that set new standards in the quality of analysis available to the global on-line betting andmedia communities. CEOAndrewDagnall tells us more about these innovative solutions. Gaming Software CEO of the Year 2017 - UK Bettorlogic licence unique content software, including Livelogic, in-play bet stimulation for mobile and platform, and Nextbet, which uses the Amazon recommendation principle but applied to betting. The firm also analyse customer betting behaviour to create profiles of players, and thus offer more personalised content which has additional value to CRM and marketing departments. Andrew discusses these creative products in more detail and explains how they offer clients the solutions they need. “As a software company, Bettorlogic are very appreciative of this award as the success of the company is based on the quality of our IT development. Bettorlogic develop software for the betting industry and does so with two objectives in mind. We licence our software to betting companies around the globe. This software creates reasons on their site or apps why customers might have a bet on an event or a particular market event. It is driven by statistical analysis of past results to help those who bet with their decision making process. For example, Man Utd are playing Liverpool and trailing by a goal with 60 minutes played. We generate a reason why somebody might bet on this match situation, the fact that when trailing after 60 minutes against teams like Liverpool, Man Utd have drawn seven of their last nine such matches. “In addition, we analyse the anonymous betting history of a client’s customers to create a profile based on their bet preferences and behaviour. This enables operators to communicate with customers on a personalised basis and we are currently developing a solution for a client whereby 100,000 customers can have 100,000 personalised displays on whatever device their customer is using.” Overall, operating in such a vital industry with an ever growing range of clients, Andrew believes that there is great scope for further growth and development of Bettorlogic. “Ultimately, I do believe as many powerful organisations do that we live in a volatile, uncertain, complex and ambiguous world (VUCA). Therefore, agencies like the CIA, Pentagon and Homeland Security pay little heed to long term strategy because events change so rapidly. To achieve short term goals requires a non-pyramid management structure with committed and motivated staff. If you believe in the VUCA concept, then agility and responsibility creates opportunities, and as such we will be looking to apply these going forward to ensure Bettorlogic’s continued success.” Website: www.bettorlogic.com BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) andmucosal delivery of peptides and proteins for chronic diseases and immune-therapies. We profile the firm to find out more about the vital work it undertakes. Biotechnology CEO of the Year & Most Innovative Biotech Company – Europe BioLingus is dedicated to developing a cutting- edge and mature solution for oral formulations of macromolecules. As more and more drugs are such biological macromolecules, which typically are injected, the need to have a non-invasive technology increases over time. BioLingus’s proprietary and break-through technology is derived from applied bio- engineering, resulting in novel bio-mimetic materials. It is a cutting-edge and mature solution for oral formulations not only for peptides but also proteins, novel protein scaffolds, vaccines, immunotherapies, enzymes and also very hydrophobic small molecules. The major driver for the firm’s success is the consistent vision and persistent execution to transform the way macromolecules can be delivered. BioLingus’s long term vision is to be one of the very best companies for non-invasive delivery of biologicals. CEO Yves Decadt’s leadership style is informal and with a balance of being people and goal- and vision oriented. In a company such as BioLingus, it is important to work with senior people who have themselves a strong entrepreneurial drive, and want to excel in their work at a global scale, and as such Yves’ role is mainly to nurture and stimulate this. Winning these awards will encourage the BioLingus team to keep developing the exciting technology and our transformational products. A second area of interest is immune-therapies, as sublingual administration allows for initiating the immune cascade in the buccal area and allows for targeting the lymphatic system directly. Overall, BioLingus’s long term goal is to become a midsize European Biotech company leading the way in non-invasive delivery of biologicals. The firm wants to become a fully integrated company, including the manufacturing and commercialisation of its products in selected countries and regions, and this will remain the firm’s ongoing focus as it looks towards a bright and exciting future. Website: www.biolingus.ch